Nebenwirkungen · Prasugrel Viatris (previously Prasugrel Mylan)
Prasugrel Viatris 5 mg film-coated tablets Prasugrel Viatris 10 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-289522 · Präparat HOS-287204
a Centrally adjudicated events defined by the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria. b Other standard therapies were used as appropriate. c Any intracranial haemorrhage or any clinically overt bleeding associated with a fall in haemoglobin ≥5 g/dL. d Life-threatening bleeding is a subset of TIMI major bleeding and includes the types indented below. Patients may be counted in more than one row. e ICH = intracranial haemorrhage. f Clinically overt bleeding associated with a fall in haemoglobin of ≥3 g/dL but <5 g/dL.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-02T11:47:00Z · SHA-256 7beae4b62105463f66fe595711eeda85a009d76c25474934e99431a1a655597e · Passage e4afe9948e2219fa8b5228c657dce1066943eefc7b87d610d6dd5a21f17dc542 · Zeichen 2973–3543 im Abschnitt